Solid Tumors
Conditions
Keywords
CP-4126, Cancer, Metastatic, Solid tumours, Gemzitabine, Gemzar
Brief summary
At step 1, patients with advanced solid tumors will receive CP-4126 capsules following a dose escalation schedule until the maximum tolerated dose is reached. At step 2, 20 patients will be randomized. They will receive at days 1 and 8 in a double cross design either oral CP-4126 at the recommended dose or gemcitabine 1000mg/m2 intravenously. At both steps, the schedule of treatment will be day 1, 8, 15 q4w until complete response or disease worsening/ progressing. All further treatment at step 2 will be oral CP-4126.
Detailed description
This is a multicentre clinical study conducted in Belgium and in The Netherlands. The study is a phase I divided in 2 steps: The first step is a dose escalation to define the RD. At the second step the PK profile of oral CP-4126 will be compared with the PK profile of IV gemcitabine. In addition, the study is conducted to characterize the tolerability of oral CP-4126, to evaluate its bioavailability, and to make a preliminary assessment of antitumor activity in patients with solid tumours.
Interventions
DRUGCP-4126
Step 1: Dose escalation oral CP-4126 until maximum tolerated dose. Step 2: Oral CP-4126 day 1 and 15 + IV Gemcitabine 1000 mg/m2 day 8 in a 4 week schedule until complete response or disease worsening / progression
DRUGGemcitabine
Step 1: Dose escalation oral CP-4126 until maximum tolerated dose Step 2: Oral CP-4126 day 8 and 15 + IV Gemcitabine 1000 mg/m2 day 1 in a 4 week schedule until complete response or disease worsening / progression
Sponsors
Clavis Pharma
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Histologically or cytologically confirmed solid tumour diagnosis 2. Locally advanced or metastatic disease, for which there is no known effective treatment 3. Performance Status 0 - 2 according to ECOG (Eastern Cooperative Oncology Group) Performance Status 4. Age 18 years or more 5. Life expectancy \> 3 months 6. Adequate hematological and biological functions: 7. Signed informed consent
Exclusion criteria
1. Symptomatic brain metastases 2. Current peripheral neuropathy of grade \> 1 according to the National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 3. Radiotherapy * to more than 30 % of bone marrow * single dose up to 8 Gy * less than one week prior to the study treatment * of the upper GI tract 4. Mucositis of the upper digestive tract, including stomatitis 5. Participation in another therapeutic clinical study within 30 days of enrolment or during this clinical study 6. Previous anticancer therapy (chemotherapy, hormone therapy or immunotherapy) within 30 days prior to the first dose of oral CP-4126 \[6 weeks for mitomycin C and BCNU (= carmustine) and CCNU (=lomustine)\] 7. Requirement of concomitant treatment with a non-permitted medication including alternative drugs and high doses of vitamins 8. History of allergic reactions to gemcitabine 9. Presence of any serious concomitant systemic disorders incompatible with the clinical study (e.g. uncontrolled inter-current illness including ongoing or active infection) 10. Presence of any significant central nervous system or psychiatric disorder(s) that would hamper the patient's compliance 11. Pregnant or breast feeding women 12. Absence of adequate contraception for both male and female fertile patients for the duration of the study; and also for six months after last treatment 13. Known positive status for HIV and/or hepatitis B or C 14. Any reason why, in the investigator's opinion, the patient should not participate 15. Condition that impairs ability to swallow pills 16. Coeliac disease or any other lipid malabsorption syndrome 17. Drug and/or alcohol abuse
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Step 1: MTD of oral CP-4126 in patients with advanced solid tumours, followed by establishing the recommended dose | 6 months |
| Step 2: Pharmacokinetic parameters comparison of oral CP-4126 with IV gemcitabine | 12 months |
Secondary
| Measure | Time frame |
|---|---|
| Tolerability of oral CP-4126 | 12 months |
| Biovailability of oral CP-4126 | 12 months |
| Preliminary assessment of antitumor activity of oral CP-4126 | 18 months |
Countries
Belgium, Netherlands
Outcome results
None listed